Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma
Phase 2
Completed
NCT03568461
| Condition | Follicular Lymphoma |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Novartis Pharmaceuticals |
|---|
| Status | Completed |
|---|
| Enrollment | 98 participants |
|---|
| Interventions | tisagenlecleucel |
|---|
| Start date | Nov 12, 2018 |
|---|
| Completion date | Nov 24, 2020 |
|---|
| Results posted | Jul 22, 2022 |
|---|
Summary
This is a multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in adult patients with relapsed or refractory FL.
Complete Response Rate (CRR) Per Independent Review Committee (IRC) Assessment
1 year · Percentage of participants
| CTL019 | 68.1 Percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.